The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
Reads0
Chats0
TLDR
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.Abstract:
The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.read more
Citations
More filters
Journal ArticleDOI
Recent advances in the phencyclidine model of schizophrenia.
TL;DR: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP and the findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia.
Journal ArticleDOI
Practice guideline for the treatment of patients with schizophrenia
Marvin I. Herz,Robert Paul Liberman,T. H. McGlashan,Jeffrey A. Lieberman,Richard Jed Wyatt,Stephen R. Marder,P. Wang,C. Allgulander,Ross J. Baldessarini,R. Balon,A. S. Bellack,C M Jr Berlin,C. H. Blackington,Peter F. Buckley,D. G. Carlson,J. Cott,Francine Cournos,P. Desai,L. Dickstein,Wayne Fenton,W. A. Fisher,Lois T. Flaherty,R. Freedman,Marc Galanter,E. Galton,Rohan Ganguli,L. K. Garrettson,S. Goldfinger,L. S. Goldman,M. Z. Goldstein,T. R. Gordy,S. H. Gray,Monica R. Green,W. M. Greenberg,John G. Gunderson,L. L. Hall,E. Haller,E. Hanin,L. Hawkins,T. W. Hester,T. Horn,J. K. Hsiao,N. V. Juthani,John M. Kane,A. Kayser,H. D. Kibel,R. A. Kimmich,R. R. Koegler,J. Krajeski,T. Kuehnel,J.S. Lamberti,Anthony F. Lehman,J. Leunello,R. L. Martin,R. McCarley,Mark McGee,Herbert Y. Meltzer,M.-Marsel Mesulam,Jeffrey L. Metzner,Loren R. Mosher,J. A. Motto,Kim T. Mueser,R. A. Munoz,H. A. Nasrallah,J. W. Newcomer,Lewis A. Opler,G. N. Peterson,M. Rapaport,Michelle Riba,V. I. Rickert,A. Rifkin,J. S. Rivenbark,S. Robertson,P. Ruiz,W. G. Ryan,M. O. Sanderson,R. B. Schiffer,P. M. Schyve,R. H. Sebring,W. W. Shen,D. Shore,G. M. Simpson,H. E. Soufi,L. I. Stein,N. Stotland,J. Strauss,D. Sundberg,D. Svendsen,Mauricio Tohen,M. Tsuang,J. G. Wagnitz,Richard D. Weiner,W. D. Weitzel,L. J. Wilkerson,D. Wingerson,C A Jr Zarate,J. Zito,Howard Zonana +97 more
Journal ArticleDOI
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht,Andrea Cipriani,Andrea Cipriani,Loukia M. Spineli,Dimitris Mavridis,Deniz Örey,Franziska Richter,Myrto Samara,Corrado Barbui,Rolf R. Engel,John R. Geddes,Werner Kissling,Marko Paul Stapf,Bettina Lässig,Georgia Salanti,John M. Davis +15 more
TL;DR: A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Journal ArticleDOI
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Nancy C. Andreasen,William T. Carpenter,John M. Kane,Robert A. Lasser,Stephen R. Marder,Daniel R. Weinberger +5 more
TL;DR: The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
Journal ArticleDOI
The Hierarchical Taxonomy of Psychopathology (HiTOP): A Dimensional Alternative to Traditional Nosologies
Roman Kotov,Robert F. Krueger,David Watson,Thomas M. Achenbach,Robert R. Althoff,R. Michael Bagby,Timothy A. Brown,William T. Carpenter,Avshalom Caspi,Lee Anna Clark,Nicholas R. Eaton,Miriam K. Forbes,Kelsie T. Forbush,David Goldberg,Deborah S. Hasin,Steven E. Hyman,Masha Y. Ivanova,Donald R. Lynam,Kristian E. Markon,Joshua D. Miller,Terrie E. Moffitt,Leslie C. Morey,Stephanie N. Mullins-Sweatt,Johan Ormel,Christopher J. Patrick,Darrel A. Regier,Leslie Rescorla,Camilo J. Ruggero,Douglas B. Samuel,Martin Sellbom,Leonard J. Simms,Andrew E. Skodol,Tim Slade,Susan C. South,Jennifer L. Tackett,Irwin D. Waldman,Monika A. Waszczuk,Thomas A. Widiger,Aidan G. C. Wright,Mark Zimmerman +39 more
TL;DR: The HiTOP promises to improve research and clinical practice by addressing the aforementioned shortcomings of traditional nosologies and provides an effective way to summarize and convey information on risk factors, etiology, pathophysiology, phenomenology, illness course, and treatment response.
References
More filters
Journal ArticleDOI
The Brief Psychiatric Rating Scale
John E. Overall,Donald R. Gorham +1 more
TL;DR: The Brief Psychiatric Rating Scale (BRS) as mentioned in this paper was developed to provide a rapid assessment technique particularly suited to the evaluation of patient change, and it is recommended for use where efficiency, speed, and economy are important considerations.
Journal ArticleDOI
Negative Symptoms in Schizophrenia: Definition and Reliability
TL;DR: The developed Scale for the Assessment of Negative Symptoms has excellent interrater reliability and the five symptom complexes defined by the scale have good internal consistency, which indicates that the conceptual organization of the scale is also cohesive.
Journal ArticleDOI
Negative v positive schizophrenia. Definition and validation.
TL;DR: Criteria for dividing the schizophrenic syndrome into three subtypes was developed: positive, negative, and mixed schizophrenia, and significant differences were noted using external validators such as premorbid adjustment, indices of cognitive dysfunction, ventricular brain ratio, and course in hospital.
Journal ArticleDOI
Molecular pathology of schizophrenia: more than one disease process?
TL;DR: In Florence showed some symptomatic improvement with only minor side effects, but this requires confirmation in a controlled trial, and another approach is based on the finding that suppressor lymphocyte activity is depressed during acute relapses in multiple sclerosis.
Journal ArticleDOI
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
TL;DR: The authors describe the Quality of Life Scale (QLS), a 21-item scale based on a semistructured interview designed to assess deficit symptoms and thereby fill an important gap in the range of instruments now available.